NORD Announces $145,000 in Seed Grants to Drive Innovation Across Four Critically Underserved Rare Diseases

QUINCY, Mass. — The National Organization for Rare Disorders (NORD®), the leading national nonprofit serving more than 30 million Americans living with rare diseases, has officially announced the recipients of its latest funding cycle. Delivering a total of $145,000 in seed grants, the initiative targets four critically underserved conditions that have historically lacked sufficient research attention, funding, and therapeutic options.

The grants have been awarded to researchers conducting groundbreaking studies on appendix cancer and pseudomyxoma peritonei (ACPMP), epidermodysplasia verruciformis (EV), Peutz-Jeghers syndrome (PJS), and partial trisomy 6q. This vital financial backing is made possible through a collaborative effort involving the ACPMP Research Foundation—a NORD member patient advocacy organization—alongside the pseudomyxoma peritonei, Peutz-Jeghers syndrome, and epidermodysplasia verruciformis communities, Dylan’s Rare Chromosome Dream Team, and the partial trisomy 6q community.

The funding arrives at a critical juncture for the rare disease community. With fewer than 5% of the approximately 10,000 known rare diseases currently possessing an FDA-approved therapy, early-stage seed grants serve as a vital catalyst for scientific discovery. These grants provide the necessary momentum for researchers to generate preliminary data, publish peer-reviewed findings, and ultimately attract larger-scale investments from major entities such as the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), or corporate sponsors.

Tracey Sikora, NORD Vice President of Research and Clinical Programs, expressed deep enthusiasm for the potential impact of the selected projects.

"Huge congratulations to our seed grant recipients — Drs. Sommariva, Ahuja, and Piovani! Their groundbreaking work represents a major leap forward for everyone affected by ACPMP, EV, PJS, and Partial Trisomy 6q," said Sikora. "We’re thrilled to champion innovative research that directly tackles the urgent, unmet needs of rare disease communities. We can’t wait to see how their insights will transform patient care and drive the future of rare disease research."

The three distinguished researchers receiving the latest round of NORD seed grants are focusing on distinct, highly specialized areas of rare disease investigation, utilizing advanced methodologies ranging from molecular targeting to privacy-preserving artificial intelligence and stem cell modeling.

The first study, spearheaded by Dr. Sommariva, is titled "Analysis of TROP2 expression in Pseudomyxoma Peritonei (PMP)." Pseudomyxoma peritonei is a rare and challenging condition where mucin-producing tumor cells spread throughout the abdominal cavity. While cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can greatly improve survival and quality of life for many patients, a significant portion of individuals cannot be treated with this method. Furthermore, systemic chemotherapy options remain severely limited, often serving merely as palliative measures.

Sommariva’s research focuses on a promising potential therapeutic target: the trophoblast cell surface antigen 2 (TROP2). Specific agents targeting TROP2 have already been developed and approved by the FDA for other solid tumors. Preliminary results have confirmed overexpression of TROP2 in PMP tumor cells. The primary aim of the new study is to expand and strengthen this initial evidence, while gaining deeper insights into the role of TROP2 in PMP pathogenesis. Establishing this foundational understanding is a crucial prerequisite for identifying a new target for combinatory and adjuvant therapies, potentially opening doors to entirely new treatment paradigms for patients.

The second and third studies are led by Dr. Ahuja, who is tackling two distinct hereditary and high-risk conditions utilizing advanced technology to bridge critical gaps in clinical care.

NORD Awards Seed Grants to Advance Breakthroughs in Rare Disease Research - National Organization for Rare

Ahuja’s first project, titled "Quantifying Malignancy and Treatment Effectiveness in EV: A Real-World Evidence Study of Surveillance Gaps," addresses epidermodysplasia verruciformis (EV). Individuals with EV face an exceptionally high lifetime risk of developing skin cancer due to specific genetic mutations coupled with persistent human papillomavirus (HPV) infections. Despite this severe risk, real-world data regarding surveillance practices and treatment outcomes remains severely limited.

To overcome this hurdle, Ahuja’s project utilizes advanced, privacy-preserving artificial intelligence to securely extract critical clinical details—such as specific HPV subtypes, skin cancer recurrence patterns, and lesion locations—directly from unstructured dermatopathology reports. By translating this otherwise hidden information into robust real-world evidence, the study aims to quantify current surveillance gaps and help establish standardized, evidence-based care guidelines designed to improve malignancy-free survival for the EV community.

Ahuja’s second investigation, titled "Risk-Stratification of PJS Complications: A RWE Study on STK11 Variant Effects on Emergency Surgery and Cancer Onset," turns its focus to Peutz-Jeghers Syndrome (PJS). PJS is a rare hereditary condition that carries a high lifetime risk of severe gastrointestinal complications and aggressive cancers. Currently, standard screening guidelines fail to account for the specific genetic mutations that actively drive the disease.

To address this deficiency, Ahuja is once again employing advanced, privacy-preserving artificial intelligence. The technology will be used to securely extract complex genetic data from medical records and directly correlate specific STK11 mutations with the age of onset for emergency surgeries and malignancies. By transforming this real-world data into actionable evidence, the research team aims to help establish precision, variant-specific surveillance protocols. These protocols are intended to prevent life-threatening emergencies and significantly improve long-term clinical outcomes for individuals living with PJS.

The fourth seed grant has been awarded to Dr. Piovani for a study titled "Partial Trisomy 6q: Clinical Characterization, Genomic Profiling, and Patient-Specific iPSC Models for Functional Disease Investigation." This project aims to provide a much-needed deeper understanding of partial trisomy 6q, a rare chromosomal disorder characterized by a partial duplication of the long arm of chromosome 6. Because so little is currently known about the condition, accurate diagnosis and genetic counseling remain exceptionally challenging for affected individuals and their families.

Piovani’s project will combine clinical and genomic information with patient-derived induced pluripotent stem cell (iPSC) models to investigate how partial trisomy 6q affects human development at a cellular level. By doing so, the study will uncover the underlying biological mechanisms driving the disorder. Ultimately, the results will provide invaluable resources for the rare disease community, laying a strong foundation for future research aimed at improving patient care, diagnostic accuracy, and therapeutic development.

NORD’s Rare Disease Research Grant Program has a long-standing history of fostering scientific breakthroughs. Since 1989, NORD has awarded more than $9 million in research grants to advance scientific discovery for rare diseases that lack adequate treatment and funding. The impact of these early-stage grants extends far beyond initial funding rounds. NORD’s program has successfully jump-started urgent rare disease research, supported numerous peer-reviewed scientific publications, and directly contributed to the development of two FDA-approved treatments.

For more information about NORD’s research grant programs, ongoing studies, and ways to support rare disease initiatives, visit rarediseases.org/advancing-research/research-grant-programs.

Founded in 1983, the National Organization for Rare Disorders (NORD®) is an independent, nonprofit, nonpartisan organization dedicated to improving the health and well-being of the more than 30 million Americans living with rare diseases. Working in active partnership with over 350 disease-specific member patient organizations and a robust Rare Disease Centers of Excellence network spanning more than 170 medical and research institutions and children’s hospitals nationwide, NORD continues to advance care, research, education, and advocacy on behalf of the entire rare disease community.

Layla Zulfa

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya